A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients

Inclusion Criteria: * Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar) or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test. * Subject who fully understands conditions of clinical trial. * Subject who agrees to participate and spontaneously sign the ICF Exclusion Criteria: * Known hypersensitivity to any component of ilaprazole, Amoxicillin and Levofloxacin * Subjects who are taking contraindicated medications for experimental and concomitant drug. * Patients with abnormal levels in the laboratory tests Total Bilirubin, Creatinine\> 1.5 times upper limit of normal AST, ALT, Alkaline phosphatase, BUN\> 2 times upper limit of normal Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of the study. * Pregnant and/or lactating women * Reproductive aged women not using contraception * Uncontrolled diabetics * Uncontrolled hypertension * Uncontrolled liver dysfunction * Alcoholics * Subjects with a history of digestive malignancy within 5 years * Subjects with a history of gastrectomy or esophagectomy Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption. * Subjects participating in a clinical trial before another trial wihin 30 days * Inconsistence judged subject by researcher